These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 3607781)
1. Interaction of etoposide and cisplatin in an in vitro tumor model. Durand RE; Goldie JH Cancer Treat Rep; 1987; 71(7-8):673-9. PubMed ID: 3607781 [TBL] [Abstract][Full Text] [Related]
2. Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II). Tsai CM; Gazdar AF; Venzon DJ; Steinberg SM; Dedrick RL; Mulshine JL; Kramer BS Cancer Res; 1989 May; 49(9):2390-7. PubMed ID: 2706626 [TBL] [Abstract][Full Text] [Related]
3. Etoposide enhances the antitumor effects of cisplatin in gastric cancer cells. Hotta T; Tanimura H; Yamaue H; Iwahashi M; Tani M; Tsunoda T; Noguchi K; Mizobata S; Arii K; Terasawa H Anticancer Res; 1997; 17(2A):885-9. PubMed ID: 9137422 [TBL] [Abstract][Full Text] [Related]
4. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells. Foroodi F; Duivenvoorden WC; Singh G Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028 [TBL] [Abstract][Full Text] [Related]
5. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology. Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906 [TBL] [Abstract][Full Text] [Related]
6. Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell lines. Hand A; Pelin K; Halme M; Ekman A; Mattson M; Vallas M; Mattson K; Linnainmaa K; Husgafvel-Pursiainen K Anticancer Drugs; 1993 Jun; 4(3):365-8. PubMed ID: 8395259 [TBL] [Abstract][Full Text] [Related]
7. Lack of synergy between cisplatin and cytarabine against ovarian carcinoma in vitro. Howell SB; Gill S Cancer Treat Rep; 1986 Mar; 70(3):409-10. PubMed ID: 3955553 [TBL] [Abstract][Full Text] [Related]
8. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Bible KC; Kaufmann SH Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999 [TBL] [Abstract][Full Text] [Related]
9. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal. Adjei AA; Budihardjo II; Rowinsky EK; Kottke TJ; Svingen PA; Buckwalter CA; Grochow LB; Donehower RC; Kaufmann SH Clin Cancer Res; 1997 May; 3(5):761-70. PubMed ID: 9815747 [TBL] [Abstract][Full Text] [Related]
10. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts. Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935 [TBL] [Abstract][Full Text] [Related]
11. THNLA-1: a DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo. Papadopoulou MV; Ji M; Bloomer WD In Vivo; 1996; 10(1):49-57. PubMed ID: 8726811 [TBL] [Abstract][Full Text] [Related]
12. Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin. Meczes EL; Pearson AD; Austin CA; Tilby MJ Br J Cancer; 2002 Feb; 86(3):485-9. PubMed ID: 11875719 [TBL] [Abstract][Full Text] [Related]
13. [Combination of etoposide with cisplatin or cyclophosphamide in the treatment of mouse Lewis lung carcinoma]. Uchida T; Okamoto K; Nishikawa K; Takahashi K Gan To Kagaku Ryoho; 1986 Jan; 13(1):75-9. PubMed ID: 3753643 [TBL] [Abstract][Full Text] [Related]
14. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo. Donnelly ET; Kelley M; Rockwell S Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460 [TBL] [Abstract][Full Text] [Related]
15. Synergism of cisplatin and mitomycin C in sensitive and resistant cell subpopulations of a tumor model. Durand RE Int J Cancer; 1989 Nov; 44(5):911-7. PubMed ID: 2511158 [TBL] [Abstract][Full Text] [Related]
16. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft. Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274 [TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Cheng MF; Chatterjee S; Berger NA Oncol Res; 1994; 6(6):269-79. PubMed ID: 7865902 [TBL] [Abstract][Full Text] [Related]
18. In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model. Kanzawa F; Nishio K; Fukuoka K; Sunami T; Saijo N Cancer Chemother Pharmacol; 1999; 43(5):353-63. PubMed ID: 10100589 [TBL] [Abstract][Full Text] [Related]
19. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Gershenson DM; Morris M; Burke TW; Levenback C; Matthews CM; Wharton JT Obstet Gynecol; 1996 Apr; 87(4):527-31. PubMed ID: 8602303 [TBL] [Abstract][Full Text] [Related]
20. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]